ARCHIVES

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

Letter to the Editors: Scientists, Media Shouldn’t Overstate “Breakthroughs”

May 29, 1998

ONS Backs Independent Nursing Research, Splits From ASCO On Meetings

September 3, 1982

Funding Opportunity: EPA, NIEHS Set Aside $10M For Research On Disease Prevention In Children

September 19, 1997

In Brief: Melanoma Precursors Consensus Conference Planned, DRCC Board Raps Centers Budget Cut

May 20, 1983

House Medicare Reform Bill Takes A smaller Bite In Drug Reimbursement

June 20, 1997